Ocrelizumab significantly reduced both relapses and disability progression in two Phase III studies in MS
30 June 2015 | By Victoria White
Roche has announced positive results from two studies evaluating ocrelizumab compared with interferon beta-1a in people with relapsing multiple sclerosis...